SciClone Pharmaceuticals

Focus: SciClone Pharmaceuticals is a small molecule-focused pharmaceutical company headquartered in Shanghai with a diversified pipeline spanning oncology, virology, and immunology. The company operates primarily in the China market with a portfolio of clinical-stage assets across multiple therapeutic areas.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Open Jobs

About SciClone Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow SciClone Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ELacestrant

ESR1 Gene Mutation

N/A

Clinical Trials (1)

NCT06544577Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

N/A

Help build intelligence for SciClone Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline with 24 programs across multiple phases (4 Phase 3 programs providing near-term catalysts)
Exposure to high-unmet-need oncology programs (pancreatic cancer, NSCLC, neuroblastoma, biliary tract cancer)
Strategic presence in China pharmaceutical market with global clinical development infrastructure

Watch Out For

Zero active job postings suggest either frozen hiring or minimal expansion phase
Limited public financial data and revenue information makes stability assessment difficult
Small molecule focus in increasingly biologics-dominated landscape may limit long-term relevance

Generated by Claude from SciClone Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SCV-07

Chronic Hepatitis C

N/A

Clinical Trials (1)

NCT01310205Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

N/A

A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

Breast Cancer Metastatic

N/A

Clinical Trials (1)

NCT07076680A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer

N/A

Endocrine therapy

ESR1 Gene Mutation

N/A

Clinical Trials (1)

NCT06548919Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

N/A

CPX

Cystic Fibrosis

Phase 1

Clinical Trials (1)

NCT00004428Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis

Phase 1

Thymalfasin

EGFR Mutation Positive Non Small Cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT02906163First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2

PT-112 Injection

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT03439761An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma

Phase 1/2

PT-112

Advanced Solid Tumor

Phase 1/2

PT-112

Biliary Tract Cancer

Phase 1/2

Clinical Trials (1)

NCT05357196PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors

Phase 1/2

SCV-07

Chronic Hepatitis C

Phase 2

Clinical Trials (1)

NCT00968357Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

Phase 2

Placebo

Oral Mucositis

Phase 2

Clinical Trials (1)

NCT00756951Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer

Phase 2

Thymalfasin

Advanced Solid Tumor

Phase 2

Clinical Trials (1)

NCT05790447Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Phase 2

SCV-07

Oral Mucositis

Phase 2

Clinical Trials (1)

NCT01247246Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

Phase 2

Thymalfasin

Non-Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT02906150Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Phase 2

Thymalfasin

Carcinoma, Hepatocellular

Phase 2

Clinical Trials (1)

NCT00082082A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

Phase 2

RP101

Pancreatic Cancer

Phase 2

Clinical Trials (1)

NCT00550004Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Phase 2

thymalfasin

Hepatitis C

Phase 3

Clinical Trials (1)

NCT00039962Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Phase 3

Thymosin alpha 1

Chronic Hepatitis C

Phase 3

Clinical Trials (1)

NCT01178996Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Phase 3

thymalfasin

Hepatitis C

Phase 3

Clinical Trials (1)

NCT00040027Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Phase 3

RRx-001 + eLOOP Device

Carcinoma, Small Cell Lung

Phase 3

Thymosin alpha 1

Sepsis

Phase 3

Clinical Trials (1)

NCT02867267The Efficacy and Safety of Ta1 for Sepsis

Phase 3

curative resection

Curable Hepatitis B Virus-Related Hepatocellular Carcinoma

Phase 4

Clinical Trials (1)

NCT02281266Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Phase 4

Pegylated Interferon-alpha2a

Chronic Hepatitis B

Phase 4

Naxitamab

Neuroblastoma

Phase 4

Clinical Trials (1)

NCT06047535Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

Phase 4